Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

American Academy Of Dermatology In Brief

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble: Dandruff sufferers who use conditioner following pyrithione zinc anti-dandruff shampoo should choose a PTZ formula "to ensure that anti-dandruff protection is maintained," as a non-PTZ conditioner could decrease the shampoo's efficacy, according to a study presented by Dianna Keneally, Procter &Gamble, et al., at the American Academy of Dermatology annual meeting March 3-7 in San Francisco. The study compared .5% platelet PTZ-containing conditioner with a cosmetic conditioner, following use of a 1% platelet PTZ-containing shampoo. Cosmetic conditioner washed away "significant amounts" of PTZ compared to PTZ conditioner and shampoo only, researchers conclude. P&G recently introduced reformulated Head & Shoulders with PTZ (1"The Tan Sheet" Jan. 9, 2006, p. 8)...

You may also be interested in...



P&G Reformulates Head & Shoulders Line To “Reduce Scalp Itch By 60%”

Procter & Gamble's introduction of Head & Shoulders HydraZinc marks the brand's most significant upgrade in 40 years, according to the company

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel